Related Experiment Video
Updated: Jun 21, 2026
10:40
Characterization of Adipocyte-Derived Extracellular Vesicle Secretion Using a CD63-GFP Reporter Mouse Model In Vivo and In Vitro
Published on: December 5, 2025
An adiponectin-like molecule with antidiabetic properties
Thierry Sulpice1, Bénédicte Prunet-Marcassus, Cécile Molveaux
1Physiogenex, Prologue Biotech, 31682 Labège Innopole cedex, France. t.sulpice@physiogenex.com
Endocrinology
|July 18, 2009
Summary
A novel recombinant adiponectin fragment, rgAd110-244, shows therapeutic potential for treating insulin resistance and diabetes. This fragment effectively improves glucose homeostasis and reduces body weight gain in mice with diet-induced obesity and insulin resistance.
Area of Science:
- Metabolic disorders
- Endocrinology
- Pharmacology
Background:
- Adiponectin plays a crucial role in regulating glucose metabolism and inflammation.
- Insulin resistance, often associated with obesity and type 2 diabetes, presents a significant global health challenge.
- Current treatments for insulin resistance have limitations, necessitating the development of novel therapeutic strategies.
Purpose of the Study:
- To investigate the therapeutic potential of a recombinant globular domain of adiponectin (rgAd110-244) in treating insulin resistance and diabetes.
- To evaluate the effects of both acute and chronic administration of rgAd110-244 on glucose homeostasis and related metabolic parameters in a mouse model.
Main Methods:
- High-fat diet (HFD) was used to induce insulin resistance, diabetes, and weight gain in mice.
- Mice received intravenous infusions or subcutaneous injections of varying doses of rgAd110-244.
- Glucose utilization rates, insulin sensitivity, plasma free fatty acid levels, and hepatic glucose production were assessed.
- Molecular markers of glucose metabolism in muscle tissue were analyzed.
Main Results:
- rgAd110-244 dose-dependently reduced hyperglycemia and improved insulin sensitivity by increasing whole-body glucose utilization and glycolysis.
- The recombinant fragment enhanced insulin's ability to reduce plasma free fatty acids.
- Acute treatment improved glucose homeostasis and increased key signaling proteins (phospho-Akt, GSK-3beta, AMPK) in muscle.
- Chronic treatment with rgAd110-244 improved fasting glycemia, insulin sensitivity, and reduced body weight gain.
Conclusions:
- A recombinant adiponectin fragment (rgAd110-244) demonstrates significant efficacy in treating diet-induced insulin-resistant diabetes in mice.
- rgAd110-244 improves glucose homeostasis through mechanisms involving enhanced glucose uptake and utilization.
- These findings support the further pharmacological investigation of rgAd110-244 as a potential novel therapeutic agent for insulin-resistant diabetes.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...